Feb
3
Development Of DNA Drugs Gives Hope To Lupus Patients
February 3, 2010 | |
A generation of DNA-peer compounds, class R inhibitory oligonucleotides (INH-ODNs), father been shown to effectively inhibit cells responsible an eye to the chronic autoimmune influence lupus. Researchers writing in BioMed Central’s open access journal Arthritis Research & Cure possess demonstrated the anti-riotous effects of the INH-ODNs in both in vitro and mouse experiments.
Petar Lenert, from the University of Iowa, worked with a team of researchers to develop and test the compounds. He said, “The increased potency of assort R INH-ODNs on the side of certain cells interested in lupus flare-ups will help patients by providing specific inhibition, yet allowing them to originate a safeguarding immune response when needed”.
Lenert and his colleagues found that their INH-ODN drugs, composed of double-stranded DNA-predilection analogues carrying autoimmune-inhibitory sequences, were able to selectively stunt the vocation of autoreactive B cells and dendritic cells. When given to mice with lupus, the compounds delayed demise and reduced kidney damage.
Systemic lupus erythematosus, more commonly known altogether as lupus, is thought to influence around a million people in the USA, but prevalence varies by country and ethnicity. It is much more common in women than men and there is currently no known cure. During periodic ‘flares’, the immune system of people with the fettle mounts an attack on cells and tissues throughout the body, resulting in a choice of symptoms including the symbolic ‘butterfly rash’ across the cheeks. With further testing, Lenert and his colleagues hope that class R INH-ODNs may turn another weapon in the fight against the disease.
DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cubicle and dendritic cell activation in vitro and autoantibody casting in lupus-prone MRL-Fas lpr/lpr mice in vivo
Petar Lenert, Kei Yasuda, Liliana Busconi, Patrice Nelson, Courtney Fleenor, Radhika S Ratnabalasuriar, Peter L Nagy, Robert F Ashman, Ian R Rifkin and Ann Marshak-Rothstein
Arthritis Research & Psychoanalysis http://arthritis-inquire into.com/
Start:
Graeme Baldwin
BioMed Central
Comments
You must be logged in to post a comment.
Jose Burden